A Study of LY3509754 in Healthy Non-Japanese and Japanese Participants

• Status: Active, not recruiting
• Trial end date: 2021-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The main purpose of this study in healthy participants is to learn more about the safety of LY3509754 and any side effects that might be associated with it. Blood tests will be performed to check how much LY3509754 gets into the bloodstream and how long it takes the body to eliminate it.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Eli Lilly and Company
• Treatments: Itraconazole; Midazolam

Criteria

Inclusion Criteria:

• Overtly healthy males or females, as determined by medical history and physical examination.

• Body mass index (BMI) within the range of 18 to 35 kilograms per meter squared (kg/m²) in Parts A, B, and C. In Part D (Japanese participants), body weight between 50 and 85 kg and BMI within the range of 18 to 28 kg/m².

Exclusion Criteria:

• Have previously completed or withdrawn from this study or any other study investigating LY3509754, and have previously received LY3509754.

• Women of childbearing potential are excluded from the trial.